Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration by Jeanine Pignatelli, Sumanta Goswami,

Slides:



Advertisements
Similar presentations
HES1 Is a Master Regulator of Glucocorticoid Receptor– Dependent Gene Expression by Javier R. Revollo, Robert H. Oakley, Nick Z. Lu, Mahita Kadmiel, Maheer.
Advertisements

by Kevin J. Paavola, Harwin Sidik, J
SP Cancer Metastasis Summary Hypothesis: We hypothesize that miRNAs regulate breast cancer cell invasiveness and metastasis by synergistically targeting.
Comment on “Chromosomal Instability and Tumors Promoted by DNA Hypomethylation” and “Induction of Tumors in Mice by Genomic Hypomethylation” by Allen S.
by Qisheng Peng, Shikha Malhotra, James A. Torchia, William G. Kerr, K
Homozygous deletions within chromosome 9q23.
Peter T. Simpson, Leonard M. Da Silva, Sunil R. Lakhani  Cancer Cell 
سرطان الثدي Breast Cancer
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Lymphoma spread? Target CD47-SIRPα!
Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.
Expression of CD36 and psap in a TMA of human ovarian cancer patients
Macrophage-specific ablation of Vegfa in PyMT implant tumors blocks blood vessel permeability and tumor cell intravasation at the TMEM. A and C, immunofluorescence.
Neutrophils, Wounds, and Cancer Progression
Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.
HER-2/neu mRNA detection by gene expression profiling
John Condeelis, Jeffrey W. Pollard  Cell 
Effect of VKORC1 Haplotype Combination on Clinical Warfarin Dose - Common haplotypes (H1, H2, H7, H8, and H9) were clustered with use of the UPGMA method.
LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.
(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.
Fig. 1. Detection of circulating tumor DNA in CRPC patients.
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
FAK overexpression in invasive human breast cancer and DCIS
A, PTEN loss signature score in resected SQCLC brain metastases.
Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,
Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.
L1-expressing cells preferentially migrate into the wound edge.
CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.
Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.
Ki-67 expression is determined by the cell-cycle stage.
Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.
Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.
by Wei-Yi Cheng, Tai-Hsien Ou Yang, and Dimitris Anastassiou
EN1-associated chromatin complexes in breast cancer cells.
EN1 expression in breast cancer and clinical outcome.
ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.
Mir-128 reduction in breast cancer tissues correlates chemotherapy resistance and poor patient survival. Mir-128 reduction in breast cancer tissues correlates.
Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.
Expression of versican promoted breast cancer cell tumor formation and self-renewal in vivo. Expression of versican promoted breast cancer cell tumor formation.
In situ analysis of human breast tissue shows the down-regulation of Spry isoforms in breast cancer. In situ analysis of human breast tissue shows the.
PD-1 expression in ovarian cancer.
MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.
Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.
The Role of TIPE2 Protein in Invasive Breast Carcinoma
Delineating cancer evolution with single-cell sequencing
Schematic model illustrating how paracrine signaling drives LPS-stimulated cytokine secretion. Schematic model illustrating how paracrine signaling drives.
Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.
A, Selected 4 quantitative imaging features significantly associated with 3 imaging subtypes, including tumor volume, tumor sphericity, tumor homogeneity.
Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.
Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.
Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.
A and B, linearity of the preamplification step shown by a similar expression pattern of ERα mRNA in four breast tumor samples pre– and post–linear amplification.
Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.
In vivo shRNA screening in PDXs from 3 patients with melanoma.
Fig. 1 RNA methyltransferase METTL14 and demethylase ALKBH5 promote growth and invasion of breast cancer cells. RNA methyltransferase METTL14 and demethylase.
Fig. 4 In vivo siRIPK4 delivered by HNTs inhibits tumor promotion of T24 bladder cancer cells in an in situ model of bladder cancer (n = 12 rats in each.
Immunohistochemical determination of TIM-3 expression in ccRCC.
Subtype classification of breast functional screening results.
Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.
CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.
Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.
Loss of NQO1 expression inhibits invasion of NSCLC
Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.
Fig. 8 Immune correlates of protection.
Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.
GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.
Presentation transcript:

Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration by Jeanine Pignatelli, Sumanta Goswami, Joan G. Jones, Thomas E. Rohan, Evan Pieri, Xiaoming Chen, Esther Adler, Dianne Cox, Sara Maleki, Anne Bresnick, Frank B. Gertler, John S. Condeelis, and Maja H. Oktay Sci. Signal. Volume 7(353):ra112-ra112 November 25, 2014 ©2014 by American Association for the Advancement of Science

Correlation of Mena isoform expression to TMEM score. Correlation of Mena isoform expression to TMEM score.(A) TMEM microanatomic cancer cell TEM sites visualized by IHC. TC, Mena-expressing tumor cells; EC, CD31-expressing vascular endothelial cells; M, CD68-expressing macrophages. Scale bars, 300 μm (left) and 50 μm (right). (B and C) Scatter plots of relative MenaINV transcript expression against TMEM score in the entire cohort of 100 IDCs (B) or by clinical subtype (C). Data were analyzed by rank-order correlation. The differences in slopes between subtypes were not statistically significant as shown by the regression model fit to the rank-transformed data. n, number of tumor cases. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science

Correlation of MenaINV-TMEM scores in different grades of human IDCs Correlation of MenaINV-TMEM scores in different grades of human IDCs.(A) Scatter plots of relative MenaINV transcript expression against TMEM score in IDCs of different grades. Correlation of MenaINV-TMEM scores in different grades of human IDCs.(A) Scatter plots of relative MenaINV transcript expression against TMEM score in IDCs of different grades. Data were analyzed with Spearman’s rank-order correlation. The differences in slopes between grades were not statistically significant as shown by the regression model fit to the rank-transformed data. (B) Representative microscopy of poorly differentiated (upper), moderately differentiated (lower), and well-differentiated (bottom) IDCs triple-stained for TMEM. TMEM sites are indicated by circles. Scale bar, 100 μm. (C) TMEM score (left panel) and relative MenaINV transcript abundance (right panel) according to tumor grade. Median, 5th and 95th percentile for MenaINV fold change, and TMEM score are presented for well-differentiated (n = 9), moderately differentiated (n = 40), and poorly differentiated (n = 51) tumors. Analyses were done using the Mann-Whitney U test at a statistical significance threshold of 0.008. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science

Correlation of E-cadherin and TMEM and MenaINV scores. Correlation of E-cadherin and TMEM and MenaINV scores.(A and B) E-cadherin abundance in tumor tissues classified as either (A) low TMEM and low MenaINV (scores <10 and <1, respectively) or high TMEM and high MenaINV (scores >50 and >5, respectively). (C) Representative images showing staining scores of 0 (none) to 3 (strong). Data are means ± SEM from ten 40× fields scored from 10 cases in each group. P < 0.001, number of cells in the low TMEM-MenaINV group that had moderate to strong E-cadherin staining (2 and 3) compared with that in the high TMEM-MenaINV group. P < 0.0001, number of cells in the high TMEM-MenaINV group that had none to weak E-cadherin staining (0 and 1) compared with that in the low TMEM-MenaINV group. Data were analyzed with unpaired, two-tailed Student’s t tests assuming equal variances and an α level of 0.05. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science

iTEM assays using human patient IDC cells obtained from FNA biopsies. iTEM assays using human patient IDC cells obtained from FNA biopsies.(A) Fold increase in the number of cells from ERPR+ or TN cases that crossed a HUVEC monolayer in the presence of macrophages (Φ) relative to the number that crossed in the absence of macrophages. Data are means ± SEM from three experiments. **P < 0.005, ***P < 0.0005, by two-tailed Student’s t tests assuming equal variances. (B) MenaINV or Mena11a transcript expression in cells that crossed the HUVEC monolayer relative to that in the loaded cell population. Data are from 16 patient cases. (C) Average MenaINV and Mena11a isoform expression in iTEM-competent cells from (B) grouped by clinical subtype. Data were not significantly different by a Student’s t test. (D) Apical z-sections from the iTEM assay. Tumor cells, green; macrophages, blue; HUVEC junctions (ZO-1), red. Squares indicate dissociating HUVEC junctions, magnified below. Right: Representative z-stacks by clinical subtype. Data are representative of each from the 16 cases in (B). (E) MenaINV and Mena11a transcript expression in iTEM-competent cells from TN human tissue transplants HT17 and HT39. Data are means ± SEM from three mice each. (F) Apical z-sections of the iTEM assay with HT17 tumor cells as in (D). Images are representative of three experiments. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science

MenaINV is required for macrophage-induced iTEM in MDA-MB-231 TN breast cancer cells. MenaINV is required for macrophage-induced iTEM in MDA-MB-231 TN breast cancer cells.(A) Transcript abundance for total Mena, Mena11a, and MenaINV in parental MDA-MB-231 cells transfected with one of three MenaINV-targeted siRNAs. (B) iTEM of MDA-MB-231 cells after MenaINV depletion in the presence or absence of macrophages (Φ). (C) iTEM of MDA-MB-231 cells expressing GFP-tagged MenaINV, alone or cotransfected with MenaINV-targeted siRNA (1). iTEM was performed in the presence of macrophages. Data in (A) to (C) are means ± SEM from three experiments. *P < 0.05, **P < 0.005, ***P < 0.0005, by two-tailed Student’s t tests assuming equal variances. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science

CSF1R expression in iTEM-competent cells differs among breast cancer subtypes. CSF1R expression in iTEM-competent cells differs among breast cancer subtypes.(A) The number of macrophages associating with tumor cells during iTEM, presented as a ratio by clinical subtype. Data are means ± SEM from twelve 63× microscopic fields in two to three cases each. *P < 0.05 compared with that in ERPR+/HER2– cases. (B and C) CSF1R transcript abundance in iTEM-competent cells from each of 15 cases analyzed across clinical subtypes (B). Data in (C) are means ± SEM by clinical subtype shown in (B). (D) Effect of mouse-specific CSF-1R antibodies or human-specific CSF-1R antibodies on iTEM of ERPR+/HER2–, ERPR–/HER2+ (HER2+), and TN cancers. Data are means ± SEM from three cases per subtype relative to the background (tumor cells cross without the presence of macrophages). Control, tumor cells cross in the presence of macrophages. (E and F) CSF1R transcript abundance in iTEM-competent cells from patient tumor transplants HT17 and HT39 (E), and the effect of mouse- or human-specific CSF-1R functionally blocking antibodies on iTEM capacity. Data are means ± SEM from five mice per tumor sample. **P < 0.005, ***P < 0.0005. Statistical analyses in (A), (C), (D), and (F) used two-tailed Student’s t tests assuming equal variances. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science

Primary human macrophages increase iTEM of primary human breast cancer cells. Primary human macrophages increase iTEM of primary human breast cancer cells.(A) Number of iTEM-competent cells from TN human tissue transplants HT17 and HT39 in the presence or absence of primary human macrophages (Φ). (B) Representative apical z-sections of the iTEM assay demonstrating HT39 cells (green) and crossing the endothelial monolayer (red) in close proximity with macrophages (blue). (C and D) Relative MenaINV and Mena11a (C) or CSF-1R (D) transcript abundance in iTEM-competent HT17 and HT39 cells in the presence of primary human macrophages. Data are means ± SEM from three mice for each tumor. ***P < 0.0005, two-tailed Student’s t tests assuming equal variances. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science

Model of MenaINV- and macrophage-mediated tumor cell invasion and TEM Model of MenaINV- and macrophage-mediated tumor cell invasion and TEM.ITEM-competent human breast cancer cells from all clinically relevant subtypes display MenaINV high/Mena11a low isoform expression and perivascular macrophages promote endothelia Model of MenaINV- and macrophage-mediated tumor cell invasion and TEM.ITEM-competent human breast cancer cells from all clinically relevant subtypes display MenaINV high/Mena11a low isoform expression and perivascular macrophages promote endothelial transmigration at TMEM sites (outlined). iTEM in ERPR+/HER2– cells is promoted by paracrine CSF-1–CSF-1R signaling, whereas iTEM in HER2+ and TN cells is promoted by both paracrine and autocrine CSF-1–CSF-1R signaling. R, receptor. Jeanine Pignatelli et al., Sci. Signal. 2014;7:ra112 ©2014 by American Association for the Advancement of Science